NCT00687934已完成1 期
A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Once-Weekly in Patients With Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 53
- 试验地点
- 2
- 主要终点
- The safety and tolerability of STA-9090 (ganetespib) in cancer patients via assessment of dose limiting toxicities
研究概览
简要总结
An open-label dose escalation study of patients with solid tumors treated with STA-9090 (ganetespib)
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 25 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must be documented to be refractory or not candidates for current approved therapies.
- •Must have an ECOG status 0-
- •Peripheral neuropathy < or =
- •Must have acceptable organ and marrow function per protocol parameters.
- •No clinically significant ventricular arrythmias or ischemia.
排除标准
- •Must not be pregnant or breastfeeding.
- •Chemotherapy or radiation within 3 weeks.
- •Previous radiation to >25% of total bone marrow.
- •Previous high dose chemotherapy with autologous or allogeneic hematopoietic stem cell transplantation.
- •Primary brain tumors or active brain metastases.
- •Use of any investigational agents within 4 weeks.
- •Treatment with chronic immunosuppressants.
- •Uncontrolled, intercurrent illness.
研究组 & 干预措施
Ganetespib
Experimental
Ganetespib once weekly infusion, dose escalation study, with treatment until progression
干预措施: STA-9090 (Drug)
结局指标
主要结局
The safety and tolerability of STA-9090 (ganetespib) in cancer patients via assessment of dose limiting toxicities
时间窗: Cycle 1
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
1 期
Study of STA-9090, Administered Twice-Weekly in Patients With Solid TumorsSolid TumorsNCT00688116Synta Pharmaceuticals Corp.45
已完成
1 期
A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous LeukemiaBlast-phase Chronic Myelogenous LeukemiaALLCMLAcute Myeloid LeukemiaAcute Lymphoblastic LeukemiaAMLNCT00964873Synta Pharmaceuticals Corp.29
已完成
1 期
STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative DisordersCMLMDSMyeloproliferative DisordersAMLNCT00858572Synta Pharmaceuticals Corp.31
已完成
2 期
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)Non Small Cell Lung CancerNCT01031225Synta Pharmaceuticals Corp.113
已完成
1 期
STA-9090 in Patients With Advanced Hepatocellular CancerHepatocellular CarcinomaNCT01665937Massachusetts General Hospital16